In Short: Revolutionising Small Molecule API Manufacturing: Embracing Miniaturisation and Automation

Built Environment Matters

In this enlightening episode, Adrian La Porta, Technical Director at Bryden Wood, dives deep into the evolving landscape of pharmaceutical manufacturing, focusing on the critical role of Small Molecule Active Pharmaceutical Ingredients (APIs) in modern medicine. As the backbone of the world's most essential medications, the development and production of APIs stand at a crossroads, challenged by the increasing demand for more complex, potent, and targeted molecules. Adrian unveils the limitations of traditional batch chemistry in API manufacturing and explores the revolutionary shift towards miniaturisation, process intensification, and automation.
Join Adrian as he dissects the groundbreaking technologies reshaping R&D, highlights the inefficiencies of current manufacturing networks, and proposes a new paradigm that promises lean, agile, and environmentally sustainable drug production. He examines the potential of continuous processing and other intensification strategies to enhance chemistry, reduce waste, and improve quality, all while addressing the financial and environmental costs associated with conventional large-scale manufacturing.
This episode is a must-listen for anyone interested in the future of pharmaceuticals, from industry professionals and researchers to healthcare providers and patients.
Discover how discarding outdated methodologies in favour of innovative, modular manufacturing systems can transform the production of life-saving drugs, making them faster, safer, and more accessible to patients worldwide.

To learn more about Bryden Wood's Design to Value philosophy, visit www.brydenwood.com. You can also follow Bryden Wood on LinkedIn and Twitter.